Director at Medicus Pharma (NASDAQ: MDCX) receives 25,000 stock options at $0.50 strike

Rhea-AI Filing Summary

Medicus Pharma Ltd. director Raju Ajay received a stock option grant for 25,000 common shares. The award gives him the right to buy 25,000 shares at an exercise price of $0.50 per share. The option becomes exercisable on March 26, 2027 and expires on March 27, 2031, and his directly held option position reported in this filing totals 25,000 derivative securities.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Raju Ajay

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	25,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 25,000 shares (Direct)

Footnotes (1)

Key Figures

Options granted: 25,000 derivative securities Exercise price: $0.50 per share Underlying shares: 25,000 common shares +3 more

6 metrics

Options granted 25,000 derivative securities Stock option grant to director on March 30, 2026

Exercise price $0.50 per share Price to acquire underlying Medicus Pharma common shares

Underlying shares 25,000 common shares Shares linked to granted stock options

Options after transaction 25,000 derivative securities Total directly held derivative securities reported post-grant

Exercisable date March 26, 2027 Date from which options may be exercised

Expiration date March 27, 2031 Date on which unexercised options lapse

Key Terms

Stock Option (right to buy), derivative securities, underlying security, Grant, award, or other acquisition

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

derivative securities financial

"derivativeTransactionCount: 1 derivative securities transaction"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

underlying security financial

"underlying_security_title: Common Shares"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Raju Ajay

(Last) (First) (Middle)

TWO LIBERTY PLACE

50 S. 16TH STREET, SUITE 2710

(Street)

PHILADELPHIA PENNSYLVANIA 19102

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Medicus Pharma Ltd. [ MDCX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.5	03/30/2026		A		25,000		03/26/2027	03/27/2031	Common Shares	25,000	$0	25,000	D

Explanation of Responses:

	/s/ Raza Bokhari, as Attorney-in-Fact, for Ajay Raju	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Medicus Pharma (MDCX) director Raju Ajay report?

Raju Ajay reported receiving a stock option grant for 25,000 derivative securities. Each option gives him the right to buy one Medicus Pharma common share, reflecting a compensation-related award rather than an open-market purchase or sale.

What is the exercise price of the new MDCX stock options granted to Raju Ajay?

The granted stock options have an exercise price of $0.50 per share. This means Ajay can later purchase Medicus Pharma common shares at $0.50 each, regardless of the market price when he chooses to exercise.

When can Raju Ajay exercise his Medicus Pharma stock options?

The stock options become exercisable on March 26, 2027. From that date until expiration, Ajay can choose to convert the options into common shares at the fixed $0.50 exercise price, subject to the terms of the award.

When do the newly granted MDCX stock options to Raju Ajay expire?

The granted stock options expire on March 27, 2031. After that date, any unexercised options will lapse, and Ajay will no longer have the right to purchase Medicus Pharma common shares under this award.

How many Medicus Pharma options does Raju Ajay hold after this grant?

Following this transaction, Ajay is reported as holding 25,000 derivative securities directly. These options are each linked to one underlying Medicus Pharma common share, representing potential future equity ownership if exercised.